Standard 6-Month Regimen (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol then Isoniazid, Rifampicin for active TB)
Treatment for Drug Susceptible Tuberculosis
Typical Dosage: Isoniazid 300mg daily, Rifampicin 600mg daily, Pyrazinamide 1500-2000mg daily, Ethambutol 800-1200mg daily
Effectiveness
95%
Safety Score
58%
Clinical Trials
500
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
Isoniazid 300mg daily, Rifampicin 600mg daily, Pyrazinamide 1500-2000mg daily, Ethambutol 800-1200mg daily
Time to Effect
2-4 weeks for clinical improvement, 2 months for sputum conversion
Treatment Duration
6 months
Evidence Quality
HIGHNumber Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$400
Monitoring:$1,500
Side Effect Mgmt:$300
Total Annual:$2,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$2,316
Cost per Remission
$2,391
Standard 6-Month Regimen (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol then Isoniazid, Rifampicin for active TB) Outcomes
for Drug Susceptible Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Remission Rate
+92%
Common Side Effects
Hepatotoxicity (elevated LFTs, clinical hepatitis)
+20%
Peripheral neuropathy
+20%
GI upset (nausea, vomiting, abdominal pain)
+15%
Arthralgia
+20%
Optic neuritis
+5%
Orange/red discoloration of body fluids
+100%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov